Literature DB >> 28342816

Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report.

Mi Hwa Heo1, Hee Kyung Kim1, Hansang Lee1, Myung-Ju Ahn2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28342816     DOI： 10.1016/j.jtho.2017.03.011

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

Review 1.  Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Authors:  Jordi Remon; Laura Mezquita; Jesús Corral; Noelia Vilariño; Noemi Reguart
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 2.  The relationships between cancer and autoimmune rheumatic diseases.

Authors:  Laura C Cappelli; Ami A Shah
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-02-03       Impact factor: 4.098

3.  Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma.

Authors:  Keiko Wakabayashi; Satoko Yamamoto; Shigeo Hara; Momoko Okawara; Kumie Teramoto; Natsuko Ikeda; Yasuo Kusunoki; Masanobu Takeji
Journal:  CEN Case Rep       Date:  2021-09-15

4.  ANCA-associated pauci-immune necrotizing glomerulonephritis during the treatment with pembrolizumab.

Authors:  Meral Uner; Bassam Alhasson; Jagdeep Obhrai; Serena M Bagnasco
Journal:  Virchows Arch       Date:  2020-07-21       Impact factor: 4.064

5.  A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.

Authors:  Abhijat Kitchlu; Kenar D Jhaveri; Shikha Wadhwani; Priya Deshpande; Ziv Harel; Teruko Kishibe; Kammi Henriksen; Rimda Wanchoo
Journal:  Kidney Int Rep       Date:  2020-10-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.